# A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321

> **NCT00354861** · PHASE1 · COMPLETED · sponsor: **Immutep S.A.S.** · enrollment: 48 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** hepatitis B antigen (without alum) plus IMP321
- **BIOLOGICAL:** hepatitis B antigen alone (without alum)
- **BIOLOGICAL:** Engerix B

## Key facts

- **NCT ID:** NCT00354861
- **Lead sponsor:** Immutep S.A.S.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2005-11
- **Final completion:** 2006-02
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2008-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00354861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00354861, "A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00354861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*